We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NT-300

News List

NT-300 tablets show promise in Phase III COVID-19 trial europeanpharmaceuticalreview
April 19, 2021
Initial results suggest NT-300 (nitazoxanide extended-release tablets, 300mg) reduces progression to severe illness in mild to moderate COVID-19 patients.
Romark Initiates Trial of NT-300 for COVID-19 americanpharmaceuticalreview
August 17, 2020
Romark announced the initiation of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Phase III trial to study NT-300 as COVID-19 treatment initiated europeanpharmaceuticalreview
August 17, 2020
A Phase III trial to investigate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19 has begun.
Romark Initiates Phase 3 Clinical Trials Of NT-300 for COVID-19 americanpharmaceuticalreview
April 30, 2020
Romark will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk populations.
Romark Initiates Trials of NT-300 for COVID-19 Prevention contractpharma
April 28, 2020
In cell cultures, the active ingredient in NT-300, nitazoxanide, inhibits replication of a broad range of respiratory viruses, including SARS-CoV-2.